Growth hormone secretagogues and growth hormone releasing peptides act as orthosteric super-agonists but not allosteric regulators for activation of the G protein Gαo1 by the ghrelin receptor

Molecular Pharmacology

Volumn 76, Issue 4, 2009, Pages 802-811

  Bennett, Kirstie A ^a   Langmead, Christopher J ^b   Wise, Alan ^b   Milligan, Graeme ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

3 (2 HYDROXYPROPYLAMINO) 3 METHYL N [2,3,4,5 TETRAHYDRO 2 OXO 1 [[2' (1H TETRAZOL 5 YL) 1,1' BIPHENYL 4 YL]METHYL] 1H 1 BENZAZEPIN 3 YL]BUTANAMIDE; GHRELIN; GHRELIN RECEPTOR; GUANINE NUCLEOTIDE BINDING PROTEIN ALPHA SUBUNIT; HISTIDYL DEXTRO TRYPTOPHYLALANYLTRYPTOPHYL DEXTRO PHENYLALANYLLYSINAMIDE; IBUTAMOREN; IODINE 125;

ALLOSTERISM; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG RECEPTOR BINDING; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL;

ALLOSTERIC REGULATION; BINDING, COMPETITIVE; CELL LINE; GHRELIN; GROWTH HORMONE; GROWTH HORMONE-RELEASING HORMONE; GTP-BINDING PROTEINS; HUMANS; PEPTIDES; RECEPTORS, GHRELIN;

EID: 70349336145     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.109.056101     Document Type: Article

References (40)

1. Black JW and Leff P (1983) Operational models of pharmacological agonism. Proc R Soc Lond B Biol Sci 220:141-162.
2. Camiña JP, Lodeiro M, Ischenko O, Martini AC, and Casanueva FF (2007) Stimulation by ghrelin of p42/p44 mitogen-activated protein kinase through the GHS-R1a receptor: role of G-proteins and beta-arrestins. J Cell Physiol 213:187-200. (Pubitemid 47378807)
3. Christopoulos A, Lanzafame A, and Mitchelson F (1998) Allosteric interactions at muscarinic cholinoceptors. Clin Exp Pharmacol Physiol 25:185-194.
4. Conn PJ, Christopoulos A, and Lindsley CW (2009) Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders. Nat Rev Drug Discov 8:41-54.
5. Cummings DE, Foster-Schubert KE, and Overduin J (2005) Ghrelin and energy balance: focus on current controversies. Curr Drug Targets 6:153-169. (Pubitemid 40394311)
6. Damian M, Martin A, Mesnier D, Pin JP, and Banères JL (2006) Asymmetric conformational changes in a GPCR dimer controlled by G-proteins. EMBO J 25:5693-5702. (Pubitemid 44967753)
7. 2+ signaling and insulin release in islet beta-cells: novel signal transduction of ghrelin. Diabetes 56:2319-2327.
8. Ehlert FJ (1988) Estimation of the affinities of allosteric ligands using radioligand binding and pharmacological null methods. Mol Pharmacol 33:187-194.
9. El-Asmar L, Springael JY, Ballet S, Andrieu EU, Vassart G, and Parmentier M (2005) Evidence for negative binding cooperativity within CCR5-CCR2b heterodimers. Mol Pharmacol 67:460-469. (Pubitemid 40216739)
10. Ellis J, Pediani JD, Canals M, Milasta S, and Milligan G (2006) Orexin-1 receptorcannabinoid CB1 receptor heterodimerization results in both ligand-dependent and -independent coordinated alterations of receptor localization and function. J Biol Chem 281:38812-38824. (Pubitemid 46042008)
11. Feighner SD, Howard AD, Prendergast K, Palyha OC, Hreniuk DL, Nargund R, Underwood D, Tata JR, Dean DC, Tan CP, et al. (1998) Structural requirements for the activation of the human growth hormone secretagogue receptor by peptide and nonpeptide secretagogues. Mol Endocrinol 12:137-145. (Pubitemid 28124786)
12. Gudermann T, Kalkbrenner F, and Schultz G (1996) Diversity and selectivity of receptor-G protein interaction. Annu Rev Pharmacol Toxicol 36:429-459. (Pubitemid 26168705)
13. Holst B and Schwartz TW (2006) Ghrelin receptor mutations-too little height and too much hunger. J Clin Invest 116:637-641. (Pubitemid 43326872)
14. Holst B, Brandt E, Bach A, Heding A, and Schwartz TW (2005) Nonpeptide and peptide growth hormone secretagogues act both as ghrelin receptor agonist and as positive or negative allosteric modulators of ghrelin signaling. Mol Endocrinol 19:2400-2411. (Pubitemid 41252832)
15. Holst B, Cygankiewicz A, Jensen TH, Ankersen M, and Schwartz TW (2003) High constitutive signaling of the ghrelin receptor-identification of a potent inverse agonist. Mol Endocrinol 17:2201-2210. (Pubitemid 37352532)
16. Holst B, Frimurer TM, Mokrosinski J, Halkjaer T, Cullberg KB, Underwood CR, and Schwartz TW (2009) Overlapping binding site for the endogenous agonist, smallmolecule agonists, and ago-allosteric modulators on the ghrelin receptor. Mol Pharmacol 75:44-59.
17. Holst B, Lang M, Brandt E, Bach A, Howard A, Frimurer TM, Beck-Sickinger A, and Schwartz TW (2006) Ghrelin receptor inverse agonists: identification of an active peptide core and its interaction epitopes on the receptor. Mol Pharmacol 70:936-946. (Pubitemid 44268450)
18. Howard AD, Feighner SD, Cully DF, Arena JP, Liberator PA, Rosenblum CI, Hamelin M, Hreniuk DL, Palyha OC, Anderson J, et al. (1996) A receptor in pituitary and hypothalamus that functions in growth hormone release. Science 273:974-977. (Pubitemid 26275178)
19. Kenakin T (1995) Pharmacological proteus? Trends Pharmacol Sci 16:256-258.
20. Kojima M and Kangawa K (2005) Ghrelin: structure and function. Physiol Rev 85:495-522.
21. Langmead CJ and Christopoulos A (2006) Allosteric agonists of 7TM receptors: expanding the pharmacological toolbox. Trends Pharmacol Sci 27:475-481.
22. Leach K, Sexton PM, and Christopoulos A (2007) Allosteric GPCR modulators: taking advantage of permissive receptor pharmacology. Trends Pharmacol Sci 28:382-389. (Pubitemid 47087967)
23. Leite-Moreira AF and Soares JB (2007) Physiological, pathological and potential therapeutic roles of ghrelin. Drug Discov Today 12:276-288. (Pubitemid 46467484)
24. Malagón MM, Luque RM, Ruiz-Guerrero E, Rodríguez-Pacheco F, García-Navarro S, Casanueva FF, Gracia-Navarro F, and Castaño JP (2003) Intracellular signaling mechanisms mediating ghrelin-stimulated growth hormone release in somatotropes. Endocrinology 144:5372-5380.
25. Michel MC and Alewijnse AE (2007) Ligand-directed signaling: 50 ways to find a lover. Mol Pharmacol 72:1097-1099.
26. Milligan G (2003) Constitutive activity and inverse agonists of G protein-coupled receptors: a current perspective. Mol Pharmacol 64:1271-1276.
27. Milligan G (2007) G protein-coupled receptor dimerisation: molecular basis and relevance to function. Biochim Biophys Acta 1768:825-835. (Pubitemid 46452542)
28. Milligan G (2008) A day in the life of a G protein-coupled receptor: the contribution to function of G protein-coupled receptor dimerization. Br J Pharmacol 153 (Suppl 1):S216-S229.
29. Milligan G and Smith NJ (2007) Allosteric modulation of heterodimeric G-proteincoupled receptors. Trends Pharmacol Sci 28:615-620. (Pubitemid 350166577)
30. Motulsky HJ and Christopoulos A (2004) Fitting models to biological data using linear and nonlinear regression. A Practical Guide to Curve Fitting, Oxford University Press, New York.
31. Muccioli G, Papotti M, Locatelli V, Ghigo E, and Deghenghi R (2001) Binding of 125I-labeled ghrelin to membranes from human hypothalamus and pituitary gland. J Endocrinol Invest 24:RC7-RC9. (Pubitemid 32293633)
32. Pantel J, Legendre M, Cabrol S, Hilal L, Hajaji Y, Morisset S, Nivot S, Vie-Luton MP, Grouselle D, de Kerdanet M, et al. (2006) Loss of constitutive activity of the growth hormone secretagogue receptor in familial short stature. J Clin Invest 116:760-768. (Pubitemid 43326885)
33. Parenty G, Appelbe S, and Milligan G (2008) CXCR2 chemokine receptor antagonism enhances DOP opioid receptor function via allosteric regulation of the CXCR2- DOP receptor heterodimer. Biochem J 412:245-256. (Pubitemid 351758230)
34. Sartania N, Appelbe S, Pediani JD, and Milligan G (2007) Agonist occupancy of a single monomeric element is sufficient to cause internalization of the dimeric beta2-adrenoceptor. Cell Signal 19:1928-1938. (Pubitemid 47081383)
35. Schwartz TW and Holst B (2006) Ago-allosteric modulation and other types of allostery in dimeric 7TM receptors. J Recept Signal Transduct Res 26:107-128.
36. Urban JD, Clarke WP, von Zastrow M, Nichols DE, Kobilka B, Weinstein H, Javitch JA, Roth BL, Christopoulos A, Sexton PM, et al. (2007) Functional selectivity and classical concepts of quantitative pharmacology. J Pharmacol Exp Ther 320:1-13. (Pubitemid 46025713)
37. van der Lely AJ, Tschöp M, Heiman ML, and Ghigo E (2004) Biological, physiological, pathophysiological, and pharmacological aspects of ghrelin. Endocr Rev 25:426-457. (Pubitemid 38780667)
38. Whorton MR, Bokoch MP, Rasmussen SG, Huang B, Zare RN, Kobilka B, and Sunahara RK (2007) A monomeric G protein-coupled receptor isolated in a highdensity lipoprotein particle efficiently activates its G protein. Proc Natl Acad Sci U S A 104:7682-7687. (Pubitemid 47185966)
39. Whorton MR, Jastrzebska B, Park PS, Fotiadis D, Engel A, Palczewski K, and Sunahara RK (2008) Efficient coupling of transducin to monomeric rhodopsin in a phospholipid bilayer. J Biol Chem 283:4387-4394.
40. Wise A, Watson-Koken MA, Rees S, Lee M, and Milligan G (1997) Interactions of the alpha2A-adrenoceptor with multiple Gi-family G-proteins: studies with pertussis toxin-resistant G-protein mutants. Biochem J 321:721-728. (Pubitemid 27084881)